Race and health
|Genetics and differences|
Race and health refers to the relationship between individual health and one's race and ethnicity. Differences in health status, health outcomes, life expectancy, and many other indicators of health in different racial and ethnic groups is well documented, referred to as Health disparities. Race (human classification) is a complex concept, and the two major competing theories of race use biological definitions and social construction to define racial difference. Although this relationship can vary depending on the definitions used, race is generally used in the context of health research as a fluid concept to group populations of people according to various factors that include but are not limited to ancestry, social identity, visible phenotype, and genetic makeup. Determinants of health include environmental, social, and genetic factors.
- 1 Defining Race
- 2 Race and Disease
- 3 Environmental Factors
- 4 Genetic Factors
- 5 Controversy regarding race in biomedicine
- 6 Association studies
- 7 Human genome projects
- 8 Sources of Racial Disparities in Care
- 9 See also
- 10 References
- 11 Further reading
- 12 External links
There are various paradigms used to discuss race, including biological and social views. Definitions have changed throughout history to yield a modern understanding of race that is complex and fluid. Moreover, there is no one definition that stands, as there are many competing and interlocking ways to look at race. The terms race, genetic population, ethnicity, geographic population, and ancestry are used interchangeably in everyday discourse involving race.
Biological definitions of race encompass Essentialist and Anti-Essentialist views. The scientific community does not universally accept a single definition of race. Essentialism is a mode of thought that uses scientific data to argue that racial groups are genetically distinct populations. Essentialists describe “races as groups of people who share certain innate, inherited biological traits, aka use of biological evidence to demonstrate racial differences.” As its counterpart, Anti-essentialism uses biological evidence to demonstrate that “race groupings do not reflect patterns of human biological variation, countering essentialist claims to the contrary.”
Social definitions are commonly constructionist. Racial groups are “constructed” from differing historical, political, and economic contexts, rather than corresponding to inherited, biological variations. Proponents of the constructionist view claim that biological definitions have been used to justify racism in the past and still have the potential to be used to encourage racist thinking in the future.
Social views also better explain the ambiguity of racial definitions. An individual may self-identify as one race based on one set of determinants (for example, phenotype, culture, ancestry) while society may ascribe the person otherwise based on external forces and discrete racial standards. Dominant racial conceptions influence how individuals label both themselves and others within society. Modern human populations are becoming more difficult to define within traditional racial boundaries due to racial admixture. Most scientific studies, applications, and government documents ask individuals to self-identify race from a limited assortment of common racial categories. The conflict between self-identification and societal ascription further complicates biomedical research and public health policies. However complex its sociological roots, race has real biological ramifications; the intersection of race, science, and society permeates everyday life and influences human health via genetics, access to medical care, diagnosis, and treatment.
Race and Disease
There are myriad factors that affect health disparities between racial groups. Among these factors are genetic differences within racial populations, cultural mores, and social and environmental factors.
Health disparities, which include variations in life expectancy and prevalence of disease, due to the differences in health conditions across various ethnic populations that can be attributed to inequalities in living environment and access to healthcare may also play a role.
Single gene disorders
There are many single gene genetic disorders that differ in frequency between different populations due to the region, though many assume it to be solely based on race. Examples include:
- Cystic fibrosis, the most common life-limiting autosomal recessive disease among people of European heritage
- Sickle-cell anemia, most prevalent in populations with sub-Saharan African ancestry but also common among Latin-American, Indian, and Saudi Arab populations, as well as those people of Mediterranean regions such as Turkey, Greece, and Italy
- Thalassemia, most prevalent in populations having Mediterranean ancestry, to the point that the disease's name is derived from Greek thalasson, "sea"
- Tay–Sachs disease, an autosomal recessive disorder more frequent among Ashkenazi Jews than among other Jewish groups and non-Jewish populations
- Hereditary hemochromatosis, most common among persons having Northern European ancestry, in particular those people of Celtic descent
Multifactorial polygenic diseases
The table shows many diseases which differ in frequency between different populations. However, complex diseases are affected by multiple factors, both genetic and environmental. There is controversy over the extent to which some of these conditions are heritable, and ongoing research aims to identify the genetic loci that are linked to these diseases.
“Risk is the probability that an event will occur. In epidemiology, it is most often used to express the probability that a particular outcome will occur following a particular exposure.” Different populations are labeled “high-risk” or “low-risk” groups for various diseases due to the probability of that particular population being more exposed to certain risk factors. Beyond genetic factors, history and culture, as well as current environmental and social conditions, influence a certain population’s exposure to some factors that makes it statistically more probable to contract specific diseases. While this chart references biomedical literature, further information on these diseases can be found in various health journals. The groups described in the chart below are race-based, though the studies conducted are more specifically population-based.
|Health defined group||High-risk groups||Low-risk groups||Reference(s)|
|Alcoholism||Native Americans, Aboriginal Australians||Europeans|||
|Atrial fibrillation||European Americans||African Americans|||
|Carotid artery disease||European Americans||African Americans|||
|Coronary artery disease||European Americans||African Americans, West African men|||
|Dementia||African Americans||European Americans|||
|Focal segmental glomerulosclerosis||African Americans||European Americans|||
|Hepatitis C clearance||European Americans||African Americans|||
|HIV progression||African Americans||European Americans|||
|HIV vertical transmission||European Americans||African Americans|||
|Hypertension||African Americans, West Africans||Europeans|||
|Hypertensive heart disease||African Americans||European Americans|||
|Hypertensive retinopathy||African Americans||European Americans|||
|Intracranial haemorrhage||African Americans||European Americans|||
|Lupus nephritis with systemic lupus erythematosus||African Americans||European Americans|||
|Lung cancer||African Americans||European Americans|||
|Multiple sclerosis||Europeans||African Americans, Turkmens, Uzbeks, Native Siberians, New Zealand Maoris|||
|Myeloma||African Americans||European Americans|||
|Non-insulin dependent diabetes||African Americans, West Africans, Peninsular Arabs, Pacific Islanders, and Native Americans||European Americans, Europeans|||
|Obesity||African women, Native Americans, Pacific Islanders, Aboriginal Australians||European Americans, Europeans, Southeast Asians|||
|Osteoporosis||European Americans||African Americans|||
|Pregnancy-related death||African Americans||European Americans|||
|Prostate cancer||Africans and African Americans||European Americans|||
|Renal disease, end stage||Native Americans and African populations||European Americans, Europeans|||
|Stroke||African Americans||European Americans|||
|Systemic lupus erythematosus||African Americans, West Africans, Native Americans||Europeans|||
|Systemic sclerosis||African Americans||European Americans|||
Groups may differ in how a disease progresses. Black men who were diagnosed with HIV generally fared worse than their white and Hispanic counterparts. The percentage of men studied with very low CD4+ T-cell count, defined as fewer than 50 cells per microliter, at AIDS diagnosis was 24.1% for white men, 27.8% for Hispanic men, and 34.4% for Black men. Black men were also significantly less likely to be alive three years after diagnosis (80.6%) than Hispanic or white men, who had 85.2% and 84.5% survival rates, respectively. However, the reasons for these differences are not clear, and should not be understood as an essential difference between races, but rather as effects of social and environmental factors.
Different groups may require different preventive measures to prevent specific diseases. For example, disease prevention for melanoma, which can include proper use of sun screen and reducing the risks of sun exposure, could be targeted to groups that are much more likely to develop melanoma from sun exposure.
"Race-based medicine" is the term for medicines that are targeted at specific ethnic clusters which are shown to have a propensity for a certain disorder. The first example of this in the U.S. was when BiDil, a medication for congestive heart failure, was licensed specifically for use in American patients that self-identify as black. Previous studies had shown that African American patients with congestive heart failure generally respond less effectively to traditional treatments than white patients with similar conditions.
After two trials, BiDil was licensed exclusively for use in African American patients. Critics have argued that this particular licensing was unwarranted, since the trials did not in fact show that the drug was more effective in African Americans than in other groups, but merely that it was more effective in African Americans than other similar drugs. It was also only tested in African American males, but not in any other racial groups or among women. This peculiar trial and licensing procedure has prompted suggestions that the licensing was in fact used as a race-based advertising scheme.
Critics are concerned that the trend of research on race-specific pharmaceutical treatments will result in inequitable access to pharmaceutical innovation and smaller minority groups may be ignored. This has led to a call for regulatory approaches to be put in place to ensure scientific validity of racial disparity in pharmacological treatment.
An alternative to “race-based medicine” is personalized medicine that involves identifying genetic, genomic (i.e. genomic sequencing), and clinical information—as opposed to using race as a proxy for these data—to better predict a patient’s predisposition to certain diseases.
Health disparities refer to gaps in the quality of health and health care across racial and ethnic groups. The US Health Resources and Services Administration defines health disparities as "population-specific differences in the presence of disease, health outcomes, or access to health care." Health is measured through variables such as life expectancy and incidence of diseases.
How researchers view race is often linked to how we address racial disparities because the national administrator of health uses these research findings to implement policies.
“79 percent of African Americans had health coverage in 2009 compared to 88 percent of white Americans.” 
In multiracial societies such as the United States, racial groups differ greatly in regard to social and cultural factors such as socioeconomic status, healthcare, diet, and education. There is also the presence of racism which some see as an important explaining factor. Some argue that for many diseases racial differences would disappear if all environmental factors could be controlled for. See the article about race and health in the United States for a discussion of such factors. These factors may or may not be appropriate in other nations.
Ethnic minorities may also have specific health care needs which need to be considered by health services in order to tackle health disparities. For example, Type 2 Diabetes are more prevalent in Mexicans as a result of economic development and urbanization of regions. When populations become more urban, it increases the availability of cheap sources of fat. A study done in 1995 showed that diabetes was most prevalent in India, China, and the United States as all three countries are highly urbanized. In addition, urbanization creates jobs that are less demanding as compared to non-urban areas. This results in a change of lifestyle and choices of recreation that is typically responsible for the high levels of obesity and diabetes in Mexicans.
No two humans are genetically identical. Differences between individuals, even closely related individuals, are the key to techniques such as genetic fingerprinting. Versions of a trait, known as alleles, occur at different frequencies in different human populations; populations that are more geographically and ancestrally remote tend to differ more.
A phenotype is the "outward, physical manifestation" of an organism." For humans, phenotypic differences are most readily seen via skin color, eye color, hair color, or height; however, any observable structure, function, or behavior can be considered part of a phenotype. A genotype is the "internally coded, inheritable information" carried by all living organisms. The human genome is encoded in DNA
For any trait of interest, observed differences among individuals “may be due to differences in the genes” coding for a trait or “the result of variation in environmental condition”. This variability is due to gene-environment interactions that influence genetic expression patterns and trait heritability.
For humans, there is “more genetic variation among individual people than between larger racial groups.” In general, an average of 85% of genetic variation exists within local populations, around 7% is between local populations within the same continent, and approximately 8% of variation occurs between large groups living on different continents. Studies have found evidence of genetic differences between populations, but the distribution of genetic variants within and among human populations is impossible to describe succinctly because of the difficulty of defining a "population," the clinal nature of variation, and heterogeneity across the genome. Thus, the racialization of science and medicine can lead to controversy when the term population and race are used interchangeably.
Genes may be under strong selection in response to local diseases. For example, people who are duffy negative tend to have higher resistance to malaria. Most Africans are duffy negative and most non-Africans are duffy positive. A number of genetic diseases more prevalent in malaria-afflicted areas may provide some genetic resistance to malaria including sickle cell disease, thalassaemias, glucose-6-phosphate dehydrogenase, and possibly others.
Many theories about the origin of the cystic fibrosis have suggested that it provides a heterozygote advantage by giving resistance to diseases earlier common in Europe.
In earlier research, a common theory was the "common disease-common variant" model. It argues that for common illnesses, the genetic contribution comes from the additive or multiplicative effects of gene variants that each one is common in the population. Each such gene variant is argued to cause only a small risk of disease and no single variant is enough to cause the disease. An individual must have many of these common gene variants in order for the risk of disease to be substantial.
More recent research indicates that the "common disease-rare variant" may be a better explanation for many common diseases. In this model, rare but higher-risk gene variants cause common diseases. This model may be relevant for diseases that reduces fertility. In contrast, for common genes associated with common disease to persist they must either have little effect during the reproductive period of life (like Alzheimer's disease) or provide some advantage in the original environment (like genes causing autoimmune diseases also providing resistance against infections). In either case varying frequencies of genes variants in different populations may be an explanation for health disparities. Genetic variants associated with Alzheimer's disease, deep venous thrombosis, Crohn disease, and type 2 diabetes appear to adhere to "common disease-common variant" model.
Gene flow and admixture can also have an effect on relationships between race and race-linked disorders. Multiple sclerosis, for example, is typically associated with people of European descent, but due to admixture African Americans have elevated levels of the disorder relative to Africans.
The same gene variant, or group of gene variants, may produce different effects in different populations depending on differences in the gene variants, or groups of gene variants, they interact with. One example is the rate of progression to AIDS and death in HIV–infected patients. In Caucasians and Hispanics, HHC haplotypes were associated with disease retardation, particularly a delayed progression to death. In contrast, for African Americans, possession of HHC haplotypes was associated with disease acceleration.
Controversy regarding race in biomedicine
There is a controversy regarding race as a method for classifying humans. Different sources argue it is purely social construct or a biological reality reflecting average genetic group differences. New interest in human biological variation has resulted in a resurgence of the use of race in biomedicine.
The main impetus for this development is the possibility of improving the prevention and treatment of certain diseases by predicting hard-to-ascertain factors, such as genetically conditioned health factors, based on of more easily ascertained characteristics such as phenotype and racial self-identification. Since medical judgment often involves decision making under uncertain conditions, many doctors consider it useful to take race into account when treating disease because diseases and treatment responses tend to cluster by geographic ancestry. The discovery that more diseases than previously thought correlate with racial identification have further sparked the interest in using race as a proxy for bio-geographical ancestry and genetic buildup.
Race in medicine is used as an approximation for more specific genetic and environmental risk factors. Race is thus partly a surrogate for environmental factors such as differences in socioeconomic status that are known to affect health. It is also an imperfect surrogate for ancestral geographic regions and differences in gene frequencies between different ancestral populations and thus differences in genes that can affect health. This can give an approximation of probability for disease or for preferred treatment, although the approximation is less than perfect.
Taking the example of sickle-cell disease, in an emergency room, knowing the geographic origin of a patient may help a doctor doing an initial diagnosis if a patient presents with symptoms compatible with this disease. This is unreliable evidence with the disease being present in many different groups as noted above with the trait also present in some Mediterranean European populations. Definitive diagnosis comes from examining the blood of the patient. In the US, screening for sickle cell anemia is done on all newborns regardless of race.
The continued use of racial categories has been criticized. Apart from the general controversy regarding race, some argue that the continued use of racial categories in health care and as risk factors could result in increased stereotyping and discrimination in society and health services. Some of those who are critical of race as a biological concept see race as socially meaningful group that is important to study epidemiologically in order to reduce disparities. For example, some racial groups are less likely than others to receive adequate treatment for osteoporosis, even after risk factors have been assessed. Since the 19th century, blacks have been thought to have thicker bones than whites have and to lose bone mass more slowly with age. In a recent study, African Americans were shown to be substantially less likely to receive prescription osteoporosis medications than Caucasians. Men were also significantly less likely to be treated compared with women. This discrepancy may be due to physicians’ knowledge that, on average, African Americans are at lower risk for osteoporosis than Caucasians. It may be possible that these physicians generalize this data to high-risk African-Americans, leading them to fail to appropriately assess and manage these individuals’ osteoporosis. On the other hand, some of those who are critical of race as a biological concept see race as socially meaningful group that is important to study epidemiologically in order to reduce disparities.
David Williams (1994) argued, after an examination of articles in the journal Health Services Research during the 1966-90 period, that how race was determined and defined was seldom described. At a minimum, researchers should describe if race was assessed by self-report, proxy report, extraction from records, or direct observation. Race was also often used questionable, such as an indicator of socioeconomic status. Racial genetic explanations may be overemphasized, ignoring the interaction with and the role of the environment.
From concepts of Race to Ethnogenetic Layering
There is general agreement that a goal of health-related genetics should be to move past the weak surrogate relationships of racial health disparity and get to the root causes of health and disease. This includes research which strives to analyze human genetic variation in smaller groups than races across the world.
One such method is called ethnogenetic layering. It works by focusing on geographically identified microethnic groups. For example, in the Mississippi Delta region ethnogenetic layering might include such microethnic groups as the Cajun (as a subset of European Americans), the Creole and Black groups [with African origins in Senegambia, Central Africa and Bight of Benin] (as a subset of African Americans), and Choctaw, Houmas, Chickasaw, Coushatta, Caddo, Atakapa, Karankawa and Chitimacha peoples (as subsets of Native American Indians).
Better still may be individual genetic assessment of relevant genes. As genotyping and sequencing have become more accessible and affordable, avenues for determining individual genetic makeup have opened dramatically. Even when such methods become commonly available, race will continue to be important when looking at groups instead of individuals such as in epidemiologic research.
One area in which population categories can be important considerations in genetics research is in controlling for confounding between population genetic substructure, environmental exposures, and health outcomes. Association studies can produce spurious results if cases and controls have differing allele frequencies for genes that are not related to the disease being studied, although the magnitude of its problem in genetic association studies is subject to debate. Various techniques detect and account for population substructure, but these methods can be difficult to apply in practice.
Population genetic substructure also can aid genetic association studies. For example, populations that represent recent mixtures of separated ancestral groups can exhibit longer-range linkage disequilibrium between susceptibility alleles and genetic markers than is the case for other populations. Genetic studies can use this disequilibrium to search for disease alleles with fewer markers than would be needed otherwise. Association studies also can take advantage of the contrasting experiences of racial or ethnic groups, including migrant groups, to search for interactions between particular alleles and environmental factors that might influence health.
Human genome projects
The Human Genome Diversity Project has collected genetic samples from 52 indigenous populations.
Sources of Racial Disparities in Care
In a report by the Institute of Medicine called Unequal Treatment, three major source categories are put forth as potential explanations for disparities in health care: patient-level variables, healthcare system-level factors, and care process-level variables.
There are many individual factors that could explain the established differences in health care between different racial and ethnic groups. First, attitudes and behaviors of minority patients are different. They are more likely to refuse recommended services, adhere poorly to treatment regimens, and delay seeking care, yet despite this, these behaviors and attitudes are unlikely to explain the differences in health care.  In addition to behaviors and attitudes, biological based racial differences have been documented, but these also seem unlikely to explain the majority of observed disparities in care. 
Health System-level factors
Care Process-level Variables
- Ethnicity and health
- ACE inhibitor; a type of drugs found to work less effectively with people of African origin
- Health and intelligence
- Human stature#Average height around the world
- List of countries by life expectancy
- Ethnic bioweapon
- Social determinants of health
- Medical genetics of Jews
- Hispanic Paradox
- Category:Human genome projects
- hyperlink http://en.wikipedia.org/wiki/Health
- hyperlink: http://en.wikipedia.org/wiki/Race_(human_classification
- The Nature Of Race: How Scientists Think And Teach About Human Difference, Chapter 4: Teaching Race, Ann Morning p 114.
- Bloom, Miriam. Understanding Sickle Cell Disease. University Press of Mississippi, 1995. Chapter 2.
- Myrianthopoulos, NC, Aronson, SM (July 1966). "Population dynamics of Tay-Sachs disease. I. Reproductive fitness and selection.". American Journal of Human Genetics 18 (4): 313–27. PMC 1706099. PMID 5945951.
- Halder I, Shriver MD 2003 52–62
- Luczak, Susan E.; Wall, Tamara L.; Shea, Shoshana H.; Byun, Susan M.; Carr, Lucinda G. (2001). "Binge drinking in Chinese, Korean, and White college students: Genetic and ethnic group differences". Psychology of Addictive Behaviors 15 (4): 306–9. doi:10.1037/0893-164X.15.4.306. PMID 11767261.
- Mail & al. (eds., 2002): Alcohol Use Among American Indians and Alaska Natives: Multiple Perspectives on a Complex Problem. NIAAA Research Monograph No. 37. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism[page needed]
- Caetano, Raul; Clark, Catherine L (1998). "Trends in Alcohol-Related Problems among Whites, Blacks, and Hispanics: 1984-1995". Alcoholism: Clinical and Experimental Research 22 (2): 534. doi:10.1111/j.1530-0277.1998.tb03685.x.
- "Ethnicity and Health Disparities in Alcohol Research".
- Ruo B., Capra A. M., Jensvold N. G., Go A. S. (2004). "Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study". J. Am. Coll. Cardiol 43: 429–435.
- Gupta V. et al. (2003). "Racial differences in thoracic aorta atherosclerosis among ischemic stroke patients". Stroke 34: 408–412.
- McKeigue P.M., Shah B., Marmot M.G. (1991). "Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians". Lancet 337: 382–386. doi:10.1016/0140-6736(91)91164-P. PMID 1671422.
- Zoratti R (1998). "A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: Is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin?". Eur. J. Epidemiol 14 (1): 9–21. doi:10.1023/A:1007492202045. PMID 9517868.
- Hargrave R., Stoeklin M., Haan M., Reed B. (2000). "Clinical aspects of dementia in African-American, Hispanic, and white patients". J. Nat. Med. Assoc 92: 15–21.
- Demirovic, J. et al. Prevalence of dementia in three ethnic groups: the South Florida program on aging and health. Ann. Epidemiol. 13, 472-478 (2003).
- Kopp, J. B. & Winkler, C. HIV-associated nephropathy in African Americans. Kidney Int. S43-S49 (2003).
- Thomas D. L. et al. (2000). "The natural history of hepatitis C virus infection: host, viral, and environmental factors". JAMA 284: 450–456.
- McGinnis K. A. et al. (2003). "Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data". Am. J. Public Health 93: 1728–1733.
- Tess B. H., Rodrigues L. C., Newell M. L., Dunn D. T., Lago T. D. (1998). "Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in São Paulo State, Brazil. São Paulo collaborative study for vertical transmission of HIV-1". Aids 12: 513–520.
- Douglas J.G., Thibonnier M., Wright Jr. (1996). "Essential hypertension: Racial/ethnic differences in pathophysiology". J. Assoc. Acad. Minor. Phys. 7 (1): 16–21. PMID 8820238.
- Gaines K., Burke G. (1995). "Ethnic differences in stroke: Black-white differences in the United States population. SECORDS Investigators. Southeastern Consortium on Racial Differences in Stroke". Neuroepidemiology 14 (5): 209–239. PMID 7477665.
- Davey Smith, Neaton J. D., Wentworth D., Stamler R., Stamler J. (1998). "Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT". Lancet 351: 934–939. doi:10.1016/S0140-6736(05)60603-4.
- Wong T. Y. et al. (2003). "Racial differences in the prevalence of hypertensive retinopathy". Hypertension 41: 1086–1091.
- Bastian H. M. et al. (2002). "Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis". Lupus 11: 152–160.
- Schwartz A.G., Swanson G.M. (1997). "Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan". Cancer 79 (1): 45–52. doi:10.1002/(SICI)1097-0142(19970101)79:1<45::AID-CNCR7>3.0.CO;2-L. PMID 8988725.
- Rosati G (2001). "The prevalence of multiple sclerosis in the world: An update". Neurol. Sci. 22: 117–139.
- Songer, T.J. and Zimmet, P.Z., (1995) "Epidemiology of type II diabetes: An international perspective," Pharmacoeconomics 8 (Suppl. 1) 1-11
- Martinez N.C. (1993). "Diabetes and minority populations. Focus on Mexican Americans". Nurs. Clin. North Am. 28: 87–95.
- Hodge A.M., Zimmet P.Z. (1994). "The epidemiology of obesity". Baillieres Clin. Endocrinol. Metab 8: 577–599.
- Bohannon A.D. (1999). "Osteoporosis and African American women". J. Women's Health Gend. Based Med. 8: 609–615.
- Harper, M. A. et al. Racial disparity in pregnancy-related mortality following a live birth outcome. Ann. Epidemiol. 14, 274-279 (2004).
- Hoffman R.M., Gilliland F.D., Eley J.W. et al. (2001). "Racial and ethnic differences in advanced-stage prostate cancer: The Prostate Cancer Outcomes Study". J. Nat. Cancer Inst. 93: 388–395.
- Ferguson R., Morrissey E. (1993). "Risk factors for end-stage renal disease among minorities". Transplant. Proc. 25: 2415–2420.
- Klag M. J. et al. (1997). "End-stage renal disease in African-American and white men. 16-year MRFIT findings". JAMA 277: 1293–1298.
- Boni, R., Schuster, C., Nehrhoff, B. and Burg, G., (2002) "Epidemiology of skin cancer," Neuroendocrinol. Lett., 23 (Suppl. 2) 48-51.
- Kissela B. et al. (2004). "Stroke in a biracial population: the excess burden of stroke among blacks". Stroke 35: 426–431.
- Molokhia M., McKeigue P. (2000). "Risk for rheumatic disease in relation to ethnicity and admixture". Arthritis Res. 2 (2): 115–125. doi:10.1186/ar76. PMC 129994. PMID 11094421.
- Reveille, J. D. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr. Rheumatol. Rep. 5, 160-167 (2003).
- "Skin Cancer Rates by Race and Ethnicity". Centers for Disease Control. Retrieved 2012-04-09.
- Taylor, AL, Ziesche, S, Yancy, C, Carson, P, D'agostino Jr, R, Ferdinand, K, Taylor, M, Adams, K et al. (2004). "(November 2004). "Combination of isosorbide dinitrate and hydralazine in blacks with heart failure"". The New England Journal of Medicine 351 (20): 2049–57. doi:10.1056/NEJMoa042934. PMID 15533851.
- Exner, DV, Dries, DL, Domanski, MJ, Cohn, JN (2001). "Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared with white patients with left ventricular dysfunction". N Engl J Med 344 (18): 1351–7. doi:10.1056/NEJM200105033441802. PMID 11333991.
- Ellison, George (2006) Medicine in black and white: BiDil: race and the limits of evidence-based medicine. Significance, Volume 3, Number 3, September 2006 , pp. 118–121(4)
- Winichoff, D. E., Obasagie, O. K. (2008) Race-specific drugs: Regulatory trends in public policy. Trends in Pharmacological Sciences. http://www.geneticsandsociety.org/article.php?id=4110
- U.S. Department of Health and Human Services (HHS), Healthy People 2010: National Health Promotion and Disease Prevention Objectives, conference ed. in two vols (Washington, D.C., January 2000).[page needed]
- Goldberg, Janet; Hayes, William; Huntley, Jill (November 2004). Understanding Health Disparities. Health Policy Institute of Ohio. p. 3.
- Collins FS (November 2004). "What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era". Nature Genetics 36 (11 Suppl): S13–5. doi:10.1038/ng1436. PMID 15507997.
- Collins, Francis S. What we do and don't know about 'race', 'ethnicity', genetics and health at the dawn of the genome era. Nature Genetics Supplement, volume 36 No. 11, November 2004.
- McKenzie K (January 2003). "Racism and health". BMJ 326 (7380): 65–6. doi:10.1136/bmj.326.7380.65. PMC 1125019. PMID 12521953.
- LaVeist TA (2000). "On the study of race, racism, and health: a shift from description to explanation". International Journal of Health Services 30 (1): 217–9. doi:10.2190/LKDF-UJQ5-W1KU-GLR1. PMID 10707307.
- Johnson, Mark (2006), "Ethnicity", in Killoran, Amanda; Swann, Catherine; Kelly, Michael P., Public Health Evidence: Tackling health inequalities, Oxford University Press
- Lewontin 1972; Jorde et al. 2000a; Hinds et al. 2005
- Long and Kittles 2003
- Malaria and the Red Cell,Harvard University. 2002 url=http://sickle.bwh.harvard.edu/malaria_sickle.html
- McClellan, Jon; King, Mary-Claire (2010). "Genetic Heterogeneity in Human Disease". Cell 141 (2): 210–217. doi:10.1016/j.cell.2010.03.032. PMID 20403315.
- Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN (2003). "Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease". Nat Genet 33 (2): 177–182. doi:10.1038/ng1071. PMID 12524541.
- Cree, BA, Khan, O, Bourdette, D, Goodin, DS, Cohen, JA, Marrie, RA, Glidden, D, Weinstock-Guttman, B et al. (December 2004). "Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis". Neurology 63 (11): 2039–45. doi:10.1212/01.WNL.0000145762.60562.5D. PMID 15596747.
- Gower, B. A. et al. "Using genetic admixture to explain racial differences in insulin-related phenotypes," Diabetes 52, 1047–1051 (2003).
- Fernandez, J. R. et al. "Association of African genetic admixture with resting metabolic rate and obesity among women," Obes. Res. 11, 904-911 (2003).
- Gonzalez, E. et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc. Natl Acad. Sci. USA. 96, 12004–12009 (1999).
- Ian Whitmarsh and David S. Jones, 2010, What's the Use of Race? Modern Governance and the Biology of Difference, MIT press. Page 188. "Far from waning in the age of molecular genetics, race has been resurgent in biomedical discourse, especially in relation to a torrent of new interest in human biological variation and its quantification."
- Ian Whitmarsh and David S. Jones, 2010, What's the Use of Race? Modern Governance and the Biology of Difference, MIT press. Chapter 9.
- Satel, Sally. "I Am a Racially Profiling Doctor". The New York Times, published May 5, 2002
- Ian Whitmarsh and David S. Jones, 2010, What's the Use of Race? Modern Governance and the Biology of Difference, MIT press. Chapter 5.
- Sheldon TA, Parker H (June 1992). "Race and ethnicity in health research". Journal of Public Health Medicine 14 (2): 104–10. PMID 1515192.
- Williams DR, Lavizzo-Mourey R, Warren RC (1994). "The concept of race and health status in America". Public Health Reports 109 (1): 26–41. PMC 1402239. PMID 8303011.
- Williams DR (August 1994). "The concept of race in Health Services Research: 1966 to 1990". Health Services Research 29 (3): 261–74. PMC 1070005. PMID 8063565.
- Goodman AH (November 2000). "Why genes don't count (for racial differences in health)". American Journal of Public Health 90 (11): 1699–702. doi:10.2105/AJPH.90.11.1699. PMC 1446406. PMID 11076233.
- Jackson, F.L.C. Ethnogenetic layering (EL): an alternative to the traditional race model in human variation and health disparity studies. Annals of Human Biology, March–April 2008; 35(2): 121–144 http://informahealthcare.com/doi/abs/10.1080%2F03014460801941752
- Jackson, F. L. (2004). "Human genetic variation and health: new assessment approaches based on ethnogenetic layering". British Medical Bulletin 69: 215–235. doi:10.1093/bmb/ldh012. PMID 15226208.
- Jordge, Lynn B. and Stephen P. Wooding. "Genetic Variation, classification and 'race'". Nature, Vol. 36 Num. 11, November 2004.
- Cardon LR, Palmer LJ (2003). "Population stratification and spurious allelic association". Lancet 361 (9357): 598–604. doi:10.1016/S0140-6736(03)12520-2. PMID 12598158.
- Marchini J, Cardon LR, Phillips MS, Donnelly P (2004). "The effects of human population structure on large genetic association studies". Nat Genet 36 (5): 512–517. doi:10.1038/ng1337. PMID 15052271.
- Thomas DC, Witte JS (2002). "Point: population stratification: a problem for case-control studies of candidate-gene associations?". Cancer Epidemiol Biomarkers Prev 11 (6): 505–512. PMID 12050090.
- Wacholder S, Rothman N, Caporaso N, "Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer," Cancer Epidemiol Biomarkers Prev (2002) 11 :513–520.
- Morton NE, Collins A (1998). "Tests and estimates of allelic association in complex inheritance". Proc Natl Acad Sci USA 95 (19): 11389–11393. doi:10.1073/pnas.95.19.11389. PMC 21652. PMID 9736746.
- Hoggart CJ, Parra EJ, Shriver MD, Bonilla C, Kittles RA, Clayton DG, McKeigue PM (2003). "Control of confounding of genetic associations in stratified populations". American Journal of Human Genetics 72 (6): 1492–1504. doi:10.1086/375613. PMC 1180309. PMID 12817591.
- Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel SB, Topol EJ, Smoller JW et al. (2004). "Assessing the impact of population stratification on genetic association studies". Nat Genet 36: 388–393.
- Hoggart CJ, Shriver MD, Kittles RA, Clayton DG, McKeigue PM (2004). "Design and analysis of admixture mapping studies". American Journal of Human Genetics 74: 965–978.
- Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, Smith MW, O'Brien SJ et al. (2004). "Methods for high-density admixture mapping of disease genes". American Journal of Human Genetics 74: 979–1000.
- Smith MW, Patterson N, Lautenberger JA, Truelove AL, McDonald GJ, Waliszewska A, Kessing BD et al. (2004). ", "A high-density admixture map for disease gene discovery in African Americans". American Journal of Human Genetics 74: 1001–1013.
- McKeigue PM (2005). "Prospects for admixture mapping of complex traits". American Journal of Human Genetics 76: 1–7.
- Chaturvedi N (2001). "Ethnicity as an epidemiological determinant—crudely racist or crucially important?". Int J Epidemiol 30: 925–927.
- Collins FS, Green ED, Guttmacher AE, Guyer MS, US National Human Genome, Institute Research (2003). "A vision for the future of genomics research". Nature 422 (6934): 835–847. doi:10.1038/nature01626. PMID 12695777.
- Smedley, Brian D. (2002). Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC.: National Academies Press. pp. 7–12. ISBN 0-309-50911-4.
- Smedley, Brian D. (2002). Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC.: National Academies Press. p. 7. ISBN 0-309-50911-4.
- Smedley, Brian D. (2002). Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC.: National Academies Press. p. 8. ISBN 0-309-50911-4.
- ACE inhibitors less effective with Africans 1
- Appel JM (July 2009). "Is all fair in biological warfare? The controversy over genetically engineered biological weapons". Journal of Medical Ethics 35 (7): 429–32. doi:10.1136/jme.2008.028944. PMID 19567692.
- Bohannon AD (June 1999). "Osteoporosis and African American women". Journal of Women's Health & Gender-based Medicine 8 (5): 609–15. doi:10.1089/jwh.1.1999.8.609. PMID 10839646.
- Böni R, Schuster C, Nehrhoff B, Burg G (July 2002). "Epidemiology of skin cancer". Neuro Endocrinology Letters 23 (Suppl 2): 48–51. PMID 12163848.
- Douglas JG, Thibonnier M, Wright JT (1996). "Essential hypertension: racial/ethnic differences in pathophysiology". Journal of the Association for Academic Minority Physicians 7 (1): 16–21. PMID 8820238.
- Dvornyk V, Liu XH, Shen H, et al. (May 2003). "Differentiation of Caucasians and Chinese at bone mass candidate genes: implication for ethnic difference of bone mass". Annals of Human Genetics 67 (Pt 3): 216–27. doi:10.1046/j.1469-1809.2003.00037.x. PMID 12914574.
- "Genes, drugs and race". Nature Genetics 29 (3): 239–40. November 2001. doi:10.1038/ng1101-239. PMID 11687784.
- Farrer LA, Cupples LA, Haines JL, et al. (1997). "Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium". JAMA 278 (16): 1349–56. doi:10.1001/jama.1997.03550160069041. PMID 9343467.
- Ferguson R, Morrissey E (August 1993). "Risk factors for end-stage renal disease among minorities". Transplantation Proceedings 25 (4): 2415–20. PMID 8356618.
- Fernández JR, Shriver MD, Beasley TM, et al. (July 2003). "Association of African genetic admixture with resting metabolic rate and obesity among women". Obesity Research 11 (7): 904–11. doi:10.1038/oby.2003.124. PMID 12855761.
- Gaines K, Burke G (1995). "Ethnic differences in stroke: black-white differences in the United States population. SECORDS Investigators. Southeastern Consortium on Racial Differences in Stroke". Neuroepidemiology 14 (5): 209–39. PMID 7477665.
- Gonzalez E, Bamshad M, Sato N, et al. (October 1999). "Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes". Proceedings of the National Academy of Sciences of the United States of America 96 (21): 12004–9. doi:10.1073/pnas.96.21.12004. PMC 18402. PMID 10518566.
- Gower BA, Fernández JR, Beasley TM, Shriver MD, Goran MI (April 2003). "Using genetic admixture to explain racial differences in insulin-related phenotypes". Diabetes 52 (4): 1047–51. doi:10.2337/diabetes.52.4.1047. PMID 12663479.
- Halder I, Shriver MD (November 2003). "Measuring and using admixture to study the genetics of complex diseases". Human Genomics 1 (1): 52–62. PMID 15601533.
- Hardy J, Singleton A, Gwinn-Hardy K (May 2003). "Ethnic differences and disease phenotypes". Science 300 (5620): 739–40. doi:10.1126/science.300.5620.739. PMID 12730580.
- Hargrave R, Stoeklin M, Haan M, Reed B (January 2000). "Clinical aspects of dementia in African-American, Hispanic, and white patients". Journal of the National Medical Association 92 (1): 15–21. PMC 2640513. PMID 10800282.
- Hodge AM, Zimmet PZ (July 1994). "The epidemiology of obesity". Baillière's Clinical Endocrinology and Metabolism 8 (3): 577–99. doi:10.1016/S0950-351X(05)80287-3. PMID 7980348.
- Hoffman RM, Gilliland FD, Eley JW, et al. (March 2001). "Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study". Journal of the National Cancer Institute 93 (5): 388–95. doi:10.1093/jnci/93.5.388. PMID 11238701.
- Holden C (October 2003). "Race and medicine". Science 302 (5645): 594–6. doi:10.1126/science.302.5645.594. PMID 14576420.
- Hugot JP, Chamaillard M, Zouali H, et al. (May 2001). "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease". Nature 411 (6837): 599–603. doi:10.1038/35079107. PMID 11385576.
- Inoue N, Tamura K, Kinouchi Y, et al. (July 2002). "Lack of common NOD2 variants in Japanese patients with Crohn's disease". Gastroenterology 123 (1): 86–91. doi:10.1053/gast.2002.34155. PMID 12105836.
- Jackson FL (2004). "Human genetic variation and health: new assessment approaches based on ethnogenetic layering". British Medical Bulletin 69: 215–35. doi:10.1093/bmb/ldh012. PMID 15226208.
- Martin MP, Dean M, Smith MW, et al. (December 1998). "Genetic acceleration of AIDS progression by a promoter variant of CCR5". Science 282 (5395): 1907–11. doi:10.1126/science.282.5395.1907. PMID 9836644.
- Martinez NC (March 1993). "Diabetes and minority populations. Focus on Mexican Americans". The Nursing Clinics of North America 28 (1): 87–95. PMID 8451219.
- Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB (May 1997). "Global distribution of the CCR5 gene 32-basepair deletion". Nature Genetics 16 (1): 100–3. doi:10.1038/ng0597-100. PMID 9140404.
- McKeigue PM, Miller GJ, Marmot MG (1989). "Coronary heart disease in south Asians overseas: a review". Journal of Clinical Epidemiology 42 (7): 597–609. doi:10.1016/0895-4356(89)90002-4. PMID 2668448.
- McKeigue PM, Shah B, Marmot MG (February 1991). "Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians". Lancet 337 (8738): 382–6. doi:10.1016/0140-6736(91)91164-P. PMID 1671422.
- Molokhia M, McKeigue P (2000). "Risk for rheumatic disease in relation to ethnicity and admixture". Arthritis Research 2 (2): 115–25. doi:10.1186/ar76. PMC 129994. PMID 11094421.
- Ogura Y, Bonen DK, Inohara N, et al. (May 2001). "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease". Nature 411 (6837): 603–6. doi:10.1038/35079114. PMID 11385577.
- Risch N, Burchard E, Ziv E, Tang H (July 2002). "Categorization of humans in biomedical research: genes, race and disease". Genome Biology 3 (7): comment2007. doi:10.1186/gb-2002-3-7-comment2007. PMC 139378. PMID 12184798.
- Rosati G (April 2001). "The prevalence of multiple sclerosis in the world: an update". Neurological Sciences 22 (2): 117–39. doi:10.1007/s100720170011. PMID 11603614.
- Schwartz AG, Swanson GM (January 1997). "Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan". Cancer 79 (1): 45–52. doi:10.1002/(SICI)1097-0142(19970101)79:1<45::AID-CNCR7>3.0.CO;2-L. PMID 8988725.
- Shimizu H, Wu AH, Koo LC, Gao YT, Kolonel LN (December 1985). "Lung cancer in women living in the Pacific Basin area". National Cancer Institute Monograph 69: 197–201. PMID 3834332.
- Songer TJ, Zimmet PZ (1995). "Epidemiology of type II diabetes: an international perspective". PharmacoEconomics. 8 Suppl 1: 1–11. PMID 10158995.
- Wiencke JK (January 2004). "Impact of race/ethnicity on molecular pathways in human cancer". Nature Reviews Cancer 4 (1): 79–84. doi:10.1038/nrc1257. PMID 14708028.
- Yancy CW (August 2003). "Does race matter in heart failure?". American Heart Journal 146 (2): 203–6. doi:10.1016/S0002-8703(03)00241-2. PMID 12891183.
- Zoratti R (January 1998). "A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin?". European Journal of Epidemiology 14 (1): 9–21. doi:10.1023/A:1007492202045. PMID 9517868.
- Cultural Diversity in Healthcare Speaker Series University of Wisconsin School of Medicine and Public Health
- Cultural Diversity in Healthcare Research Symposium University of Wisconsin School of Medicine and Public Health
- Unnatural causes, videos on how racial inequalities influence health
- United States Office of Minority Health
- United Kingdom National Health Service - Ethnicity & Health
- Multicultural Mental Health Australia